NCT04076358 is a NA clinical trial of Tab-CBI in Arthritis, sponsored by University of Massachusetts, Amherst.

Who is sponsoring NCT04076358?

NCT04076358 is sponsored by University of Massachusetts, Amherst.

What drugs are being tested in NCT04076358?

Interventions in NCT04076358: Tab-CBI.

What condition does NCT04076358 study?

NCT04076358 studies Arthritis, Fatigue.

Is NCT04076358 still recruiting?

NCT04076358 is currently completed. Last updated 4 November 2020.

Last reviewed 2020-11-04 · How we verify

NCT04076358

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Tablet-based Simple Walking Intervention

Completed NA Last updated 4 November 2020

What this trial tests

NA trial testing Tab-CBI in Arthritis in 24 participants. Completed in 18 March 2020.

Timeline

23 May 2019

Primary endpoint
15 March 2020

18 March 2020

Quick facts

Lead sponsor	University of Massachusetts, Amherst
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	24
Start date	23 May 2019
Primary completion	15 March 2020
Estimated completion	18 March 2020
Sites	1 location across United States

Drugs / interventions tested

Tab-CBI

Conditions studied

Arthritis — all drugs for Arthritis →
Fatigue — all drugs for Fatigue →

Sponsor

University of Massachusetts, Amherst

Who can join

50 and older, any sex, with Arthritis or Fatigue. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this project is to pilot test the effect of a tablet-based cognitive behavioral intervention (Tab-CBI) application on older adults' a) daily steps, b) fatigue level, c) self-efficacy, and d) quality of life at Week 1 (baseline), Week 4 (intervention completion), Week 6 (booster), Week 8 (follow-up #1), and Week 10 (follow-up #2) in a sample of 24 older adults. The investigators hypothesize that (a) individuals receiving Tab-CBI will have increased daily step counts, decreased fatigue level, greater perception of self-efficacy and quality of life than those receiving current RA fatigue management, and that (b) the effects will be sustained up through 4 weeks of follow-ups after the intervention completion.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Tablet-based cognitive behavioral intervention to improve arthritis associated fatigue: A pilot study.
Choi J, Fiske S, Choi WJ, Cody JL. · · 2022 · PMID 36155313 · DOI 10.1016/j.gerinurse.2022.09.003

Verify or expand the search:

Other recruiting trials for Arthritis

Currently open trials in the same condition.

NCT05067998 — The Benefits of Natural Medicine, Vitamin IV Therapy and Supplements: Maintaining Good Health Through Nature · recruiting
NCT07284563 — Ultralow Dose PET Imaging for 18F-NaF Uptake · Phase 2 · recruiting
NCT06915012 — Impact of Biophoton Therapy on Chronic Severe Arthritis Pain · NA · recruiting
NCT06880653 — Dose Response of Exercise for Arthritis Management · NA · recruiting
NCT07106931 — Early STratification of Acute ARThritis · recruiting

Other University of Massachusetts, Amherst trials

Trials by the same sponsor.

NCT07211373 — Advancing Student Suicide Interventions With Scalable Technologies · NA · enrolling by invitation
NCT06990997 — Effects of Aphasia Identification Cards on Service Workers' Comprehension of People With Aphasia · NA · recruiting
NCT07016555 — Burning Mouth Syndrome: Symptoms and Management · EARLY_PHASE1 · recruiting
NCT06412016 — Urban Gardening and Peer Nutritional Counseling for People With HIV and Food Insecurity · NA · active not recruiting
NCT06399939 — The Function of Biphasic Sleep in Infants · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04076358 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Massachusetts, Amherst
Last refreshed: 4 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04076358.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing